A Phase Ib Trial of Pembrolizumab (MK-3475) and Trametinib Focused on Advanced KRAS Mutant Non-small Cell Lung Cancer
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Trametinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 28 Feb 2018 Planned initiation date changed from 1 Dec 2017 to 1 Aug 2018.
- 28 Feb 2018 Status changed from recruiting to not yet recruiting.
- 15 Dec 2017 Status changed from not yet recruiting to recruiting.